Questions for categories: Biotech/Pharma

Investment Rational

Oramed has developed a proprietary platform technology for the oral delivery of drugs presently administered via injection. Oramed is in Phase 3 trials for oral insulin, and through its Oravax Medical subsidiary, has a triple antigen oral COVID-19 vaccine candidate now in Phase 1 trials. Oravax announced a joint venture with Genomma Labs to commercialize the oral vaccine in Mexico.

Business Strategy

Oramed has core competencies in drug development and clinical trial management. The Company will look to sell its subsidiary's proprietary oral Covid-19 vaccine to governments and large pharma companies through partnerships and joint ventures, with relevant industry leaders in respective target regions, who will assist in obtaining local regulatory approval, carrying out sales, distribution and business development.

Core Technology

Oramed's' POD™ (Protein Oral Delivery) technology is designed to protect orally delivered proteins from enzymatic activity within the gastrointestinal tract and to enhance their absorption across the intestinal wall. This breakthrough solution brings oral protein-drug delivery closer to reality. The oral Covid vaccine combines the POD technology and VLP triple antigen approach with superior protection against variants.

Product Profile/Pipeline

The oral VLP vaccine targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, thus making the oral vaccine potentially more effective against variants of the COVID-19 virus. Now in Phase 1 trials in South Africa, Oramed is in discussions with governments and big pharma to develop and commercialize the oral vaccine globally.

What's Next?

Phase I trials for the oral Covid-19 vaccine are underway and we anticipate quickly beginning a Phase 2/3 trial following top line data. We will seek emergency use approval and begin commercializing our vaccine to countries in need. Oramed's strong cash position of $174M will allow us to efficiently continue our clinical development.